INmune Bio IncNASDAQ:INMB
- LAST PRICE10.8500
- TODAY'S CHANGE (%)-0.3200 (-2.8648%)
- Bid / Lots10.6100/ 5
- Ask / Lots12.3800/ 1
- Open / Previous Close11.3600 / 11.1700
- Day Range
- 52 Week Range
- Volume84,727
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INMB |
|---|---|---|
| 09:32 ET | 6581 | 11.36 |
| 09:34 ET | 1000 | 11.17 |
| 09:36 ET | 724 | 11.15 |
| 09:39 ET | 1098 | 10.7642 |
| 09:56 ET | 100 | 11.03 |
| 09:59 ET | 500 | 11 |
| 10:08 ET | 100 | 10.76 |
| 10:17 ET | 500 | 10.92 |
| 10:21 ET | 300 | 10.9143 |
| 10:32 ET | 3741 | 10.96 |
| 10:39 ET | 100 | 11.06 |
| 11:22 ET | 108 | 11.0635 |
| 11:33 ET | 723 | 10.91 |
| 11:44 ET | 462 | 10.99 |
| 11:51 ET | 2300 | 10.91 |
| 11:54 ET | 100 | 10.93 |
| 12:02 ET | 305 | 10.91 |
| 12:03 ET | 500 | 10.94 |
| 12:09 ET | 680 | 10.98 |
| 12:18 ET | 500 | 10.98 |
| 12:30 ET | 2906 | 10.965 |
| 12:32 ET | 100 | 10.97 |
| 12:34 ET | 110 | 10.9355 |
| 12:39 ET | 100 | 10.97 |
| 12:54 ET | 100 | 10.97 |
| 12:57 ET | 115 | 10.9985 |
| 01:01 ET | 400 | 11 |
| 01:03 ET | 300 | 11.0147 |
| 01:08 ET | 100 | 11.017 |
| 01:15 ET | 100 | 11.06 |
| 01:17 ET | 100 | 11.04 |
| 01:28 ET | 200 | 11.06 |
| 01:53 ET | 300 | 10.93 |
| 02:00 ET | 300 | 11.04 |
| 02:02 ET | 1000 | 11.04 |
| 02:18 ET | 660 | 11.05 |
| 02:20 ET | 3580 | 11.03 |
| 02:22 ET | 200 | 11.01 |
| 02:24 ET | 100 | 11.025 |
| 02:26 ET | 1489 | 11.05 |
| 02:27 ET | 100 | 11.01 |
| 02:36 ET | 100 | 11.05 |
| 02:38 ET | 500 | 11.035 |
| 02:40 ET | 1410 | 11.05 |
| 02:45 ET | 600 | 11.06 |
| 02:49 ET | 200 | 11.04 |
| 02:54 ET | 2512 | 11.04 |
| 02:56 ET | 100 | 11.04 |
| 03:00 ET | 200 | 11 |
| 03:02 ET | 300 | 11.06 |
| 03:05 ET | 697 | 11.03 |
| 03:07 ET | 600 | 10.97 |
| 03:09 ET | 800 | 11.04 |
| 03:12 ET | 300 | 11.03 |
| 03:14 ET | 1862 | 11.01 |
| 03:16 ET | 300 | 10.97 |
| 03:18 ET | 1200 | 11 |
| 03:20 ET | 824 | 10.97 |
| 03:23 ET | 1200 | 10.9913 |
| 03:25 ET | 1124 | 10.96 |
| 03:30 ET | 200 | 10.95 |
| 03:34 ET | 100 | 10.935 |
| 03:38 ET | 100 | 10.935 |
| 03:39 ET | 300 | 10.925 |
| 03:41 ET | 100 | 10.92 |
| 03:43 ET | 400 | 10.95 |
| 03:45 ET | 1000 | 10.935 |
| 03:48 ET | 300 | 10.94 |
| 03:50 ET | 816 | 10.96 |
| 03:52 ET | 700 | 11 |
| 03:54 ET | 100 | 10.99 |
| 03:56 ET | 333 | 10.925 |
| 03:57 ET | 600 | 10.91 |
| 03:59 ET | 1078 | 10.85 |
May 9, 2024
*DJ INmune Bio 1Q Loss/Shr 61c >INMB, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow JonesINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow Jones
May 7, 2024
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9, from 8:00AM ET on Tuesday May 07, 2024 by Dow Jones
8:00AM ET on Tuesday May 07, 2024 by Dow Jones
Apr 30, 2024
Apr 29, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
INmune Bio Inc | 214.6M | -5.7x | --- |
Boundless Bio Inc | 215.1M | 0.0x | --- |
Acumen Pharmaceuticals Inc | 219.3M | -3.5x | --- |
Prelude Therapeutics Inc | 219.7M | -2.1x | --- |
Compass Therapeutics Inc. | 220.1M | -4.6x | --- |
Ovid Therapeutics Inc | 223.1M | -4.4x | --- |
Company Information
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
Contact Information
- Headquarters
- 225 Ne Mizner Blvd, Suite 640BOCA RATON, FL, United States 33432
- Phone
- 858-964-3720
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Raymond Tesi
- Chief Financial Officer
- David Moss
- Chief Scientific Officer
- Mark Lowdell
- Independent Director
- Marcia Allen
- Independent Director
- Edgardo Baracchini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $214.6M |
|---|---|
Revenue (TTM) | $131.0K |
Shares Outstanding | 19.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.91 |
EPS | $-1.92 |
Book Value | $2.12 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | 1,638.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -26,209.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
